Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552386 | 0.82 | SLC2A1 (0.35) | SLC2A1MAPTPTGS2PTGS1 | |
| SCHEMBL97003 | 0.78 | GRM5 (0.46) | KMT2ANPC1RAB9ASMN1; SMN2SOS1 | |
| SCHEMBL95410 | 0.78 | MAPK1 (0.46) | MEN1KMT2AHTTNPC1LMNA | |
| SCHEMBL16960824 | 0.77 | MEN1 (0.38) | SLC2A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL233380 | 0.77 | VCAM1 (0.44) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL15094371 | 0.77 | EGFR (0.49) | SLC2A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL31195830 | 0.77 | VCAM1 (0.44) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL9996717 | 0.77 | HTT (0.38) | SLC2A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL31308753 | 0.77 | EGFR (0.49) | SLC2A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL102884 | 0.74 | TRPV4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| CN-106414480-A | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | 莫纳什大学 | 2017-02-15 | — | — | CN | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| EP-0903334-B1 | Halogenated aromatic derivatives and process for the preparation thereof | MITENI SPA (IT) | 2003-06-11 | — | — | EP | claimed |
| EP-0922693-B1 | Process for the preparation of 3-chloro-4-fluorobenzoyl chloride | CLARIANT GMBH (DE) | 2001-10-24 | — | — | EP | claimed |
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | UNIV KYOTO (JP) | 2023-09-07 | — | — | US | disclosed |
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | disclosed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | disclosed |
| US-20200125564-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2020-04-23 | — | — | US | disclosed |
| US-20180265463-A1 | Vitamin D3 Derivatives and Pharmaceutical Use Thereof | KYOTO UNIVERSITY (JP) | 2018-09-20 | — | — | US | disclosed |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-09-04 | — | — | US | disclosed |
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| US-4874770-A | Aryl-substituted (N-piperidinyl)methyl- and (N-piperidinyl) methylazoles having antipsychotic properties | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1989-10-17 | — | — | US | disclosed |
| US-4772604-A | ANTIPSYCHOTIC AGENTS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1988-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | SLC2A1 3600/4885MEN1 2632/4885KMT2A 2447/4885 |
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | SLC2A1 996/4885MEN1 1153/4885KMT2A 3128/4885 |
| US-20180265463-A1 | Vitamin D3 Derivatives and Pharmaceutical Use Thereof | VDR, CYP24A1, CYP2R1 | SLC2A1 996/4885MEN1 1153/4885KMT2A 3128/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | SLC2A1 1837/4885MEN1 2970/4885KMT2A 1395/4885 |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | VIP, PEPD, NRDC | SLC2A1 3383/4885MEN1 4056/4885KMT2A 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.